Evercore ISI analyst Cory Kasimov initiated coverage of Neurocrine with an Outperform rating and $175 price target. Ingrezza’s growth, crinecerfont’s blockbuster potential, and an intriguing neuropsych pipeline with meaningful 2H24 catalysts create a compelling set-up, the analyst tells investors in a research note. Evercore expects the commercial success of Ingrezza to continue, with the product ultimately generating more than $3B in peak sales by 2030.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NBIX:
- Neurocrine presents CAHtalyst adult study baseline characteristics, data
- Neurocrine announces initiation of Phase 1 study evaluating NBI-1076986
- Neurocrine initiates Phase 1 clinical study of NBI-1117567 in healthy adults
- Neurocrine presents data from CAHtalyst Pediatric Phase 3 clinical study
- Neurocrine price target raised to $150 from $140 at Citi